Dublin, Aug. 20, 2018 (GLOBE NEWSWIRE) -- The "Molecular Cytogenetics Market by Offering, by Technology, by Application, by End User, by Geography - Global Market Size, Share, Development, Growth, and Demand Forecast, 2014 - 2023" report has been added to ResearchAndMarkets.com's offering. Global molecular cytogenetics market is forecasted to attain revenue of $3.3 billion by 2023. The market is mainly driven by growing implementation of pharmacogenomics in personalized disease management and drug development, rising cancer cases, advancements in cytogenetic techniques, and rise in genetic-based prediction of chromosomal abnormalities. Based on offering, the molecular cytogenetics market has been categorized into consumables, software and services and instruments. Globally, the market for software and services is expected to register fastest growth, with CAGR of 10.5% during the forecast period. This can be attributed to rapid adoption of automation in laboratory process and rising preference for outsourcing of expensive services. Based on technology, the molecular cytogenetics market has been categorized into comparative genomic hybridization (CGH), fluorescence in-situ hybridization (FISH), immunohistochemistry, karyotyping and others. The karyotyping technology market for molecular cytogenetics is further categorized into spectral and virtual. In 2017, spectral karyotyping held larger share, of 66.0%, in molecular cytogenetics market, owing to the usage of these technique for the detection of complex chromosomal aberration as well as for identification of new leukaemia subgroups. During the forecast period, the molecular cytogenetics market is expected to witness fastest growth in personalized medicine application, at a CAGR of 10.1%. This growth is attributable to rise in demand for precision medicine coupled with high investments in research and development. Based on end user, the molecular cytogenetics market has been classified into clinical and research laboratories, academic research institutes, hospitals and pathology laboratories and pharmaceutical and biotechnology companies. Among these, clinical and research laboratories held the largest share as an end-user category during the historical period in this market and accounted for a 33.4 % share in 2017. Molecular cytogenetics market to witness fastest growth in Asia-Pacific (APAC) During the forecast period, the molecular cytogenetics market is projected to witness fastest growth in APAC, at CAGR of 11.8%, mainly due to the large population in the region, untapped market and entry of global players in the industry to offer cytogenetic testing. Government initiatives such as mandatory testing, funding and training programs to the researchers are some other factors that are propelling the growth of the market in the region. According to the World Bank, the healthcare expenditure of South Asia was 3.9% of its total GDP in 2000, which increased to 4.4% in 2014. The growing healthcare infrastructure in APAC is creating huge revenue generation opportunities for the pharmaceutical and biotechnology companies in the region. Market players are focusing on developing technologically advanced molecular cytogenetics products Globally, key players in the molecular cytogenetics industry are developing new instruments and tests for the molecular diagnosing, genetic screening and other tests. For instance, in July 2017, Quest Diagnostics announced the launch of a genetic screening service, QHerit. The service is for the detection of genetic risk associated to offspring through passing of heritable disorders. The QHerit Pan-Ethnic Expanded Carrier Screen is a panel of tests for the 22 heritable diseases cited under new screening guidelines issued in March 2017 by the American College of Gynecology (ACOG). Some of the other key players operating in the molecular cytogenetics industry include Abbott Laboratories, Danaher Corporation, Bio-Rad Laboratories Inc., F. Hoffmann La-Roche AG, PerkinElmer Inc., Illumina Inc, Agilent Technologies Inc and NeoGenomics Inc. Key Topics Covered Chapter 1. Research Background 1.1 Research Objectives 1.2 Market Definition 1.3 Research Scope 1.3.1 Market Segmentation By Offering 1.3.2 Market Segmentation By Technology 1.3.3 Market Segmentation By Application 1.3.4 Market Segmentation By End User 1.3.5 Market Segmentation By Geography 1.3.6 Analysis Period 1.3.7 Market Data Reporting Unit 1.3.7.1 Value 1.4 Key Stakeholders Chapter 2. Research Methodology 2.1 Secondary Research 2.2 Primary Research 2.2.1 Breakdown Of Primary Research Respondents 2.2.1.1 By Region 2.2.1.2 By Industry Participant 2.2.1.3 By Company Type 2.3 Market Size Estimation 2.4 Data Triangulation 2.5 Assumptions For The Study Chapter 3. Executive Summary Chapter 4. Introduction 4.1 Definition Of Market Segments 4.1.1 By Offering 4.1.1.1 Consumables 4.1.1.2 Software And Services 4.1.1.3 Instruments 4.1.2 By Technology 4.1.2.1 Comparative Genomic Hybridization (Cgh) 4.1.2.1.1 Array-Based Cgh 4.1.2.1.2 Standard Cgh 4.1.2.2 Fluorescence In Situ Hybridization (Fish) 4.1.2.3 Immunohistochemistry (Ihc) 4.1.2.4 Karyotyping 4.1.2.4.1 Spectral Karyotyping (Sky) 4.1.2.4.2 Virtual Karyotyping 4.1.3 By Application 4.1.3.1 Cancer 4.1.3.2 Genetic Disorders 4.1.3.3 Personalized Medicine 4.1.3.4 Others 4.1.4 By End User 4.1.4.1 Clinical And Research Laboratories 4.1.4.2 Academic Research Institutes 4.1.4.3 Hospitals And Pathology Laboratories 4.1.4.4 Pharmaceutical And Biotechnology Companies 4.1.4.5 Others 4.2 Market Dynamics 4.2.1 Drivers 4.2.1.1 Rising Pharmacogenomics For Disease Management And Drug Development 4.2.1.2 Rising Prevalence Of Cancer 4.2.1.3 Advancements In Molecular Cytogenetic Techniques 4.2.1.4 Growth In Genetic-Based Prediction Of Chromosomal Abnormalities 4.2.1.5 Increasing Molecular Cytogenetics Application In Crop Improvement 4.2.1.6 Aging Population And Its Vulnerability To Chronic Diseases 4.2.1.7 Impact Analysis Of Drivers On Market Forecast 4.2.2 Restraints 4.2.2.1 High Cost Of Cytogenetics Instruments 4.2.2.2 Lack Of Skilled Personnel 4.2.2.3 Lack Of Regulatory Framework And Insufficient Reimbursements 4.2.2.4 Impact Analysis Of Restraints On Market Forecast 4.3 Porter's Five Forces Analysis Chapter 5. Global Market Size And Forecast 5.1 By Offering 5.2 By Technology 5.2.1 Cgh Molecular Cytogenetics Market By Type 5.2.2 Karyotyping Molecular Cytogenetics Market By Type 5.3 By Application 5.4 By End User 5.5 By Region Chapter 6. North America Market Size And Forecast 6.1 By Offering 6.2 By Technology 6.2.1 Cgh Molecular Cytogenetics Market By Type 6.2.2 Karyotyping Molecular Cytogenetics Market By Type 6.3 By Application 6.4 By End User 6.5 By Country 6.5.1 U.S. Molecular Cytogenetics Market 6.5.1.1 By Offering 6.5.1.2 By Technology 6.5.1.2.1 Cgh Molecular Cytogenetics Market By Type 6.5.1.2.2 Karyotyping Molecular Cytogenetics Market By Type 6.5.1.3 By Application 6.5.1.4 By End User 6.5.2 Canada Molecular Cytogenetics Market 6.5.2.1 By Offering 6.5.2.2 By Technology 6.5.2.2.1 Cgh Molecular Cytogenetics Market By Type 6.5.2.2.2 Karyotyping Molecular Cytogenetics Market By Type 6.5.2.3 By Application 6.5.2.4 By End User Chapter 7. Europe Market Size And Forecast 7.1 By Offering 7.2 By Technology 7.2.1 Cgh Molecular Cytogenetics Market By Type 7.2.2 Karyotyping Molecular Cytogenetics Market By Type 7.3 By Application 7.4 By End User 7.5 By Country 7.5.1 Germany Molecular Cytogenetics Market 7.5.1.1 By Offering 7.5.1.2 By Technology 7.5.1.2.1 Cgh Molecular Cytogenetics Market By Type 7.5.1.2.2 Karyotyping Molecular Cytogenetics Market By Type 7.5.1.3 By Application 7.5.1.4 By End User 7.5.2 U.K. Molecular Cytogenetics Market 7.5.2.1 By Offering 7.5.2.2 By Technology 7.5.2.2.1 Cgh Molecular Cytogenetics Market By Type 7.5.2.2.2 Karyotyping Molecular Cytogenetics Market By Type 7.5.2.3 By Application 7.5.2.4 By End User Chapter 8. APAC Market Size And Forecast 8.1 By Offering 8.2 By Technology 8.2.1 Cgh Molecular Cytogenetics Market By Type 8.2.2 Karyotyping Molecular Cytogenetics Market By Type 8.3 By Application 8.4 By End User 8.5 By Country 8.5.1 Japan Molecular Cytogenetics Market 8.5.1.1 By Offering 8.5.1.2 By Technology 8.5.1.2.1 Cgh Molecular Cytogenetics Market By Type 8.5.1.2.2 Karyotyping Molecular Cytogenetics Market By Type 8.5.1.3 By Application 8.5.1.4 By End User 8.5.2 China Molecular Cytogenetics Market 8.5.2.1 By Offering 8.5.2.2 By Technology 8.5.2.2.1 Cgh Molecular Cytogenetics Market By Type 8.5.2.2.2 Karyotyping Molecular Cytogenetics Market By Type 8.5.2.3 By Application 8.5.2.4 By End User Chapter 9. LATAM Market Size And Forecast 9.1 By Offering 9.2 By Technology 9.2.1 Cgh Molecular Cytogenetics Market By Type 9.2.2 Karyotyping Molecular Cytogenetics Market By Type 9.3 By Application 9.4 By End User 9.5 By Country 9.5.1 Brazil Molecular Cytogenetics Market 9.5.1.1 By Offering 9.5.1.2 By Technology 9.5.1.2.1 Cgh Molecular Cytogenetics Market By Type 9.5.1.2.2 Karyotyping Molecular Cytogenetics Market By Type 9.5.1.3 By Application 9.5.1.4 By End User Chapter 10. MEA Market Size And Forecast 10.1 By Offering 10.2 By Technology 10.2.1 Cgh Molecular Cytogenetics Market By Type 10.2.2 Karyotyping Molecular Cytogenetics Market By Type 10.3 By Application 10.4 By End User 10.5 By Country 10.5.1 South Africa Molecular Cytogenetics Market 10.5.1.1 By Offering 10.5.1.2 By Technology 10.5.1.2.1 Cgh Molecular Cytogenetics Market By Type 10.5.1.2.2 Karyotyping Molecular Cytogenetics Market By Type 10.5.1.3 By Application 10.5.1.4 By End User Chapter 11. Global Strategic Developments 11.1 Mergers And Acquisitions 11.2 Product Launches And Approvals 11.3 Partnerships 11.4 Other Developments Chapter 12. Company Profiles 12.1 Abbott Laboratories 12.1.1 Business Overview 12.1.2 Product And Service Offerings 12.1.3 Key Financial Summary 12.2 Danaher Corporation 12.2.1 Business Overview 12.2.2 Product And Service Offerings 12.2.3 Key Financial Summary 12.3 Bio-Rad Laboratories Inc. 12.3.1 Business Overview 12.3.2 Product And Service Offerings 12.3.3 Key Financial Summary 12.4 F. Hoffmann La-Roche AG 12.4.1 Business Overview 12.4.2 Product And Service Offerings 12.4.3 Key Financial Summary 12.5 Agilent Technologies Inc. 12.5.1 Business Overview 12.5.2 Product And Service Offerings 12.5.3 Key Financial Summary 12.6 Perkinelmer Inc. 12.6.1 Business Overview 12.6.2 Product And Service Offerings 12.6.3 Key Financial Summary 12.7 Illumina Inc. 12.7.1 Business Overview 12.7.2 Product And Service Offerings 12.7.3 Key Financial Summary 12.8 Quest Diagnostics Inc. 12.8.1 Business Overview 12.8.2 Product And Service Offerings 12.8.3 Key Financial Summary 12.9 Neogenomics Inc. 12.9.1 Business Overview 12.9.2 Product And Service Offerings 12.9.3 Key Financial Summary For more information about this report visit https://www.researchandmarkets.com/research/q...cular?w=12
CONTACT: ResearchAndMarkets.com Laura Wood, Senior Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 Related Topics: Genomics
